The impact of the American Heart Association guidelines on patients treated for incomplete Kawasaki disease

Megan M Blaney1, Richard V Williams2, Igor A Areinamo3

  • 1Division of Pediatrics, University of Utah, Salt Lake City, UT, USA.

Cardiology in the Young
|September 6, 2021
PubMed

Insights

Many incomplete Kawasaki disease patients did not meet American Heart Association guidelines. Consulting pediatric cardiology improved guideline adherence for Kawasaki disease treatment.

Area of Science:

  • Pediatrics
  • Cardiology
  • Infectious Diseases

Background:

  • Kawasaki disease (KD) is a leading cause of acquired pediatric heart disease.
  • Incomplete KD diagnosis poses challenges in timely and appropriate management.
  • American Heart Association (AHA) guidelines aim to standardize incomplete KD diagnosis and treatment.

Purpose of the Study:

  • To compare the adherence to AHA guidelines for incomplete Kawasaki disease.
  • To evaluate the impact of cardiology consultation on guideline adherence.

Main Methods:

  • Retrospective cohort study of patients under 18 treated for KD.
  • Comparison of patients treated for incomplete KD based on AHA guideline adherence.
  • Analysis of demographics, clinical data, coronary artery abnormalities, and cardiology consultation.

Main Results:

  • 31% of KD patients had incomplete KD; 74% followed AHA criteria.
  • Coronary artery abnormalities were found in 42% of incomplete KD patients.
  • AHA guideline adherence was significantly higher with cardiology consultation (76% vs. 48%).

Conclusions:

  • Over 25% of incomplete KD cases did not meet AHA guidelines.
  • Pediatric cardiology consultation is associated with improved adherence to incomplete KD guidelines.
  • Consultation with pediatric cardiology experts is recommended for managing incomplete KD.
Abstract

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
286
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
65
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
581
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
70
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
59
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
71